Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 15/20 | 0.59 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL29827826 | 1.00 | CYP3A4 (0.65) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29828267 | 0.98 | CYP3A4 (0.68) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29828084 | 0.98 | CYP3A4 (0.68) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29828249 | 0.98 | CYP3A4 (0.68) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29827898 | 0.98 | CYP3A4 (0.68) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29827961 | 0.98 | CYP3A4 (0.63) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29828254 | 0.97 | CYP3A4 (0.65) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29626966 | 0.95 | CYP3A4 (0.65) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29626970 | 0.95 | CYP3A4 (0.65) | CYP3A4CYP2D6FAP | |
| Ammonia Solution, Strong SCHEMBL29827788 | 0.89 | CYP3A4 (0.59) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-10-31 | — | — | US | disclosed |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CYP3A4 17/4885CYP2D6 18/4885FAP 419/4885 |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CYP3A4 17/4885CYP2D6 18/4885FAP 419/4885 |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | PNPO, GSTO1, CYP2C18 | CYP3A4 17/4885CYP2D6 18/4885FAP 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.